Clinical Trial Update: A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and immunogenicity of the TB vaccine AERAS-402 in HIV-negative, BCG-vaccinated adults without evidence of TB, including both…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• AERAS-402

Snippet

Sponsor: Aeras | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED